Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Asymchem Laboratories
Pharma
Eisai-Biogen, Astellas-Pfizer, Novartis—Fierce Pharma Asia
Eisai and Biogen's second Alzheimer's drug returns a victory. Astellas and Pfizer fight over a Lexiscan generic. Novartis sells a Sandoz plant.
Angus Liu
Sep 30, 2022 9:15am
Asymchem Labs in early planning for $697M manufacturing facility
Sep 27, 2022 9:51am
Takeda, Daiichi Sankyo, Dizal, Biden and more—Fierce Pharma Asia
Sep 16, 2022 10:15am
Asymchem completes construction at new Chinese production sites
Apr 7, 2022 9:40am
China’s Asymchem snaps up Snapdragon for $58M
Feb 15, 2022 9:45am
Asymchem’s API plant gets passing grade from Australian regulators
Oct 19, 2017 9:28am